RFA-GH-22-001: Enhancing Capacity for Strategic and Applied Research Activities in Support of Control and Elimination of Malaria and Other Parasitic Diseases
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2021.
Centers for Disease Control and Prevention - ERA offered grants of up to $2.4 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 4 awards worth $12.0 million in total. Applications closed on March 1, 2022.
From the official notice on Grants.gov, last changed January 18, 2022. Checked November 7, 2026.
- Award ceiling$2.4 million
- Total funding$12.0 million
- Expected awards4
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | December 20, 2021 |
|---|---|
| Deadline | March 1, 2022 |
| Archived by Grants.gov | March 2, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
N/A
Is this a realistic fit?
- Past Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention awards averaged $1.7 million; this notice allows up to $2.4 million per award.
- Most of the program's money (51% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity is to assist with the implementation of research studies that will provide critical information on ways to monitor, control, and potentially eliminate parasitic diseases including malaria. Through this funding announcement, the Division of Parasitic Diseases and Malaria seeks to fund critical research and evaluation activities with the potential to yield high impact public health findings and to improve strategies that will decrease the overall burden of parasitic diseases and increase the health and well-being of affected populations. Research topics include identifying and tracking morbidity, developing and testing better diagnostic tools, improving surveillance, and developing and evaluating interventions that can reduce or interrupt transmission of parasitic diseases including reduction of their vectors.
Who has won Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention grants before
From fiscal 2021 to 2025, Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention (93.326) awarded $345 million across 205 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Washington State University | Washington | 2 | $23.2 million |
| Association of Public Health Laboratories, Inc. (the) | Maryland | 2 | $19.6 million |
| International Centre for Diarrhoeal Disease Research, Bangladesh | 2 | $13.3 million | |
| Liverpool School of Tropical Medicine | 1 | $10.6 million | |
| California Department of Public Health | California | 1 | $10.3 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-GH-22-001 still open?
No. It closed on March 1, 2022. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Enhancing Capacity for Strategic and Applied Research Activities in Support of Control and Elimination of Malaria and Other Parasitic Diseases?
Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Enhancing Capacity for Strategic and Applied Research Activities in Support of Control and Elimination of Malaria and Other Parasitic Diseases?
Closed March 1, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.4 million each. About $12.0 million in total across about 4 awards.
Who has won Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention grants before?
The largest recipients over five fiscal years were Washington State University, Association of Public Health Laboratories, Inc. (the), International Centre for Diarrhoeal Disease Research, Bangladesh. The program made 205 awards worth $345 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)